Clariness Taps Veteran CEO Jim Corrigan to Lead Post-Merger Charge

AUSTIN, Texas – March 31, 2026 – In a move signaling a new era of aggressive growth, global patient recruitment firm Clariness today announced the appointment of industry veteran Jim Corrigan as its new Chief Executive Officer. The announcement comes just two months after the company's transformative merger with SubjectWell and includes the unveiling of a newly integrated executive leadership team, all orchestrated under the backing of private equity firm WindRose Health Investors.

The appointment positions Corrigan, a three-time CEO with a history of scaling high-growth healthcare technology and services companies, at the helm of a newly formed powerhouse in the clinical trial support sector. The combined entity aims to tackle one of the most persistent and costly challenges in modern drug development: getting patients into clinical trials efficiently and effectively.

A Post-Merger Power Play

Today's leadership announcement is the capstone of a strategic consolidation orchestrated by WindRose Health Investors. The private equity firm, which specializes in the healthcare services sector, first acquired SubjectWell in April 2024. It then engineered the merger of SubjectWell with Clariness in January 2026, creating what it hopes will become a "category-defining patient recruitment platform."

The merger was designed to be highly synergistic, combining Clariness's extensive global digital footprint and operational reach with SubjectWell's robust patient marketplace and expertise in patient experience. The newly unified company, operating under the Clariness brand, now boasts a formidable presence across more than 60 countries and the ability to support a vast range of clinical trials.

"Clariness is a global leader in an extremely important and growing segment of the clinical trial landscape," said CJ Burnes, Partner at WindRose Health Investors, in a statement. "We are excited to be partnering with Jim and believe his experiences and focus on innovation and growth makes him the right leader of Clariness through this next phase of growth."

This strategy reflects a classic private equity "buy and build" approach, where complementary assets are combined to create a single, more powerful entity capable of commanding a larger market share and offering a more comprehensive suite of services than either could alone.

A Veteran Helmsman for a Critical Challenge

In tapping Jim Corrigan, Clariness gains a leader with a deep and proven track record in the very eClinical and pharmaceutical services world it aims to serve. Before joining Clariness, Corrigan served as CEO for several key industry players, including YPrime, a provider of cloud-based eClinical solutions, and ConnectiveRx, a pharmaceutical services firm focused on patient access.

His most notable tenure was perhaps as President and CEO of ERT, a major eClinical provider, where he is credited with quadrupling the company's size. This experience in scaling complex organizations and navigating the clinical development lifecycle makes him a strategic choice to lead the integrated Clariness-SubjectWell entity. His background suggests a focus on operational excellence, technological innovation, and aggressive market expansion.

"I'm incredibly excited to step into this role at such an exciting moment," Corrigan stated. "Clariness is advancing how global patient recruitment and retention are delivered at scale, and we have the talent, capabilities, and momentum to drive meaningful impact for patients, and stronger outcomes for our customers worldwide."

Corrigan also emphasized the importance of internal culture, a key factor in successfully integrating two distinct companies. "Just as importantly, we are building a culture that supports growth, opportunity, and collaboration - ensuring our people are empowered to do their best work and grow with the company."

Tackling the Clinical Trial Bottleneck

The strategic moves by Clariness are set against the backdrop of a persistent crisis in clinical research. Industry data consistently shows that patient recruitment is the single largest cause of clinical trial delays. An estimated 80 to 85 percent of all trials fail to meet their initial enrollment timelines, leading to cascading financial losses for sponsors and, more importantly, delaying the availability of potentially life-saving treatments for patients.

The market is rapidly evolving to address this bottleneck. The industry is shifting away from traditional, site-based recruitment methods toward more sophisticated, technology-driven approaches. Key trends include the use of large-scale data analytics, artificial intelligence to identify eligible patient populations from electronic health records, and digital platforms that create a more seamless and engaging experience for potential participants. There is also a growing regulatory and ethical imperative to increase the diversity of trial participants to ensure new therapies are safe and effective for all populations.

Clariness's strategy appears purpose-built to capitalize on these trends. By combining digital reach, a massive patient database, and a focus on scientific rigor, the company aims to transform recruitment from an unpredictable variable into a powerful and predictable driver of trial success.

An Integrated Team for Global Execution

Supporting Corrigan is a newly structured executive team that blends talent from both legacy organizations, designed to ensure seamless global execution. The lineup includes:

• Janine Hart as Chief Operating Officer and Chief Compliance Officer, overseeing the company's global delivery engine.
• Gopi Krishnamurthy as Chief Technology Officer, driving platform, data, and technology innovation.
• Stefan Mayer-Eggersmann, a Clariness veteran, as President and Chief Commercial Officer, leading the go-to-market strategy.
• Karl Stubelis as Chief Financial Officer, managing financial strategy and profitable growth.
• Dr. Tobias Kruse as Chief Scientific Officer, guiding scientific strategy and the development of new services.

This C-suite structure demonstrates a clear intent to unify operations, technology, and commercial efforts under a single strategic vision.

"Clariness is defining how global patient recruitment and retention is done successfully and, with this accomplished leadership team, we are enhancing our ability to deliver across the full clinical trial journey," Corrigan added. "As a single global partner, we empower sponsors, CROs, and sites to move seamlessly from feasibility through last-patient-randomized."

With its new leadership, integrated platform, and the substantial backing of WindRose, Clariness is making a clear statement to the market. The company is no longer just a service provider but is positioning itself as an end-to-end strategic partner poised to redefine efficiency and access in the high-stakes world of clinical research.